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Abstract : C-Reactive protein （CRP） is widely used as a marker of infec-
tion, but there is insufficient evidence as to its usefulness in patients with 
community-acquired pneumonia （CAP）.  In the present study, we investigated 
the clinical usefulness of CRP in a retrospective study of 242 patients aged 
≥ 14 years who were hospitalized with CAP.  Patients were classified into 
three groups according to the number of days between disease onset and 
the initial measurement of CRP as follows : Group 1, 0-1 day ; Group 2, 2-4 
days ; Group 3, ≥ 5 days.  Patients in Groups 2 and 3, who had more severe 
pneumonia, had higher CRP levels.  Over time, CRP levels decreased in the 
responders in Groups 2 and 3 ; specically, in Group 2, median CRP levels on 
Days 0, 3, and 7 were 9.85, 5.33, and 0.81 mg/dL, respectively, compared with 
9.99, 4.29, and 0.70 mg/dL, respectively, in Group 3.  In patients not responding 
to initial treatment, median CRP levels increased from Day 0 to Day 3 （4.32 
vs. 11.70 mg/dL, respectively）.  In all non-responders, CRP levels on Day 3 
were＞ 50% of levels on Day 0.  In conclusion, when measured approximately 
48 h after disease onset, CRP is useful for evaluating the severity of pneu-
monia and predicting the response to treatment.  A good clinical outcome is 
likely when CRP levels on Day 3 are ≤ 50% of those on admission.
Key words : Community-acquired pneumonia, C-reactive protein, pneumonia, 
prognosis, severity
Introduction
　C-Reactive protein （CRP） is a representative acute phase reactant and an important 
marker of acute inammation 1）.  In Japan, CRP is a widely used indicator for the diagnosis 
of infectious diseases, as well as for evaluating patient responses to treatment.  However, the 
clinical value of monitoring CRP in patients with infection has been questioned in the US, 
and CRP was not included in the Infectious Diseases Society of America/American Tho-
racic Society Consensus Guidelines on the Management of Community-Acquired Pneumonia 
in Adults published in 2007 2）.  In addition, the 2005 Japanese Respiratory Society （JRS） 
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Guidelines for the Management of Community-Acquired Pneumonia in Adults stated that 
there was no correlation between the severity of pneumonia and CRP levels 3）.  However, 
subsequent studies reported that CRP is useful for evaluating the severity of pneumonia 
and the response to treatment4-8）, and this was stated in the 2008 JRS Guidelines for the 
Management of Hospital-Acquired Pneumonia in Adults 9）.  Such contradictory reports may 
originate from a known characteristic of CRP, namely that CRP levels vary considerably at 
different stages of an illness 10）.  In the present study, we divided patients with community-
acquired pneumonia （CAP） into three groups according to the interval between disease 
onset and the initial measurement of CRP and investigated whether CRP levels on admis-
sion reect the severity of pneumonia and whether changes in CRP levels after hospitaliza-
tion reect patient response to treatment.
Materials and Methods
Patients
　The present study was a retrospective study performed in 299 patients with a diagnosis 
of CAP who had been admitted to Kawasaki Medical School Hospital or Showa University 
Hospital （Japan） between January 2004 and March 2009.  In the present study, CAP was 
dened in accordance with the JRS Guidelines for the Management of Community-Acquired 
Pneumonia in Adults 3） as pneumonia in a patient who had not been hospitalized prior 
to its onset and who was carrying on normal activities of daily living.  CRP levels were 
determined in all patients at the time of their admission to hospital （Day 0 CRP）.  Twenty-
ve patients who received steroid therapy were excluded from the study because steroids 
inuence the kinetics of CRP.  Another 32 patients with incomplete data were also excluded 
from the study, such that data for a total of 242 patients were available for evaluation. 
Microbiological investigations were based on bacteria isolated from the sputum or from 
blood cultures obtained upon hospital admission.  In the case of Streptococcus pneumoniae 
and Legionella pneumophila, positive urinary antigen tests were also accepted.
　The study protocol was approved by the ethics committee of our institution.
Methods
　The severity of pneumonia in each patient was classied according to the A-DROP score 
（see Table 1）3）.  This scoring system was devised by modifying the CURB-65 score, which 
is a prognostic score for patients with CAP that was developed by the British Thoracic 
Society 11, 12）.  An A-DROP score of 0 is dened as mild pneumonia, a score of 1-2 indi-
cates moderate pneumonia, and a score of ≥ 3 indicates severe pneumonia.  Because the 
Day 0 CRP levels would be inuenced by the interval from the onset of pneumonia to 
hospital admission, patients were divided into the following three groups : Group 1, patients 
who were admitted to hospital on the day of onset or the following day ; Group 2, patients 
admitted 2-4 days after the onset of pneumonia ; and Group 3, patients admitted ≥ 5 days 
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after the onset of pneumonia.  The day of onset of pneumonia was dened as the day 
when fever ≥ 38℃, chest pain, purulent sputum, or difculty breathing was noted by the 
treating physician in the patient’s medical record.  The relationship between the severity 
of pneumonia and Day 0 CRP levels was investigated in each group.  In addition, Day 0 
CRP levels were compared between the three groups.  Changes in CRP levels over time 
were evaluated in relation to clinical outcome.  Patients with defervescence （temperature
＜ 38℃） and improvement of productive cough, chest pain, and dyspnea by Day 3 were 
dened as responders, whereas all other patients were dened as non-responders.  Patients 
who exhibited minimal changes in their symptoms, making improvements in symptoms dif-
cult to judge, were included in the responder group.  CRP levels were determined on Days 
0, 3, and 7 for the responders and on Days 0 and 3 for the non-responders, and the CRP 
proles of the two groups were compared.
　Statistical analyses were performed using JMPⓇ 8.0.2 software （SAS Institute, Cary, NC, 
USA）.  The Wilcoxon test, Wilcoxon signed-rank test, and logistic regression analysis were 
performed as appropriate.
Results
　The patients’ clinical proles are given in Table 2.  Of the 242 patients in the study, 15 
were classied as non-responders ; of these, 13 eventually improved after changes to their 
treatment and two died.  The average age of the responders was 58.6 years, compared with 
71.5 years in the non-responder group.  Of the 242 patients, 29 were allocated to Group 1, 
108 were allocated to Group 2, and 105 were allocated to Group 3.  Analysis of the main 
co-morbidities did not reveal any signicant differences between the responders and non-
responders.  Streptococcus pneumoniae was the most frequent isolate, followed by Haemophi-
lus inuenzae and Mycoplasma pneumoniae.
　The relationship between the severity of pneumonia and Day 0 CRP levels in each group 
is indicated in Table 3.  In Group 1, median Day 0 CRP levels of patients with mild, 
moderate, and severe pneumonia were 4.38, 6.88, and 0.67 mg/dL, respectively.  There was 
no association between the severity of pneumonia and Day 0 CRP levels.  In Groups 2 and 
Table 1.  The A-DROP scoring system （from the Japanese 
Respiratory Society guidelines）
A : Age （male ≥ 70 years, female ≥ 75 years）
D : Dehydration or blood urea nitrogen ≥ 21 mg/dL
R : Respiratory failure （SaO2＜ 90%, PaO2＜ 60 mmHg）
O : Orientation disturbed （confusion）
P : Low blood pressure （systolic blood pressure＜ 90 mmHg）
Mild, none of the ve criteria met ; Moderate, 1-2 criteria met ; 
Severe, 3 criteria met ; Extremely severe, 4-5 criteria met.
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3, median Day 0 CRP levels of patients with mild, moderate, and severe pneumonia were 
4.88, 12.40, and 11.21 mg/dL, respectively, in Group 2 patients and 7.52, 11.58, and 13.53 mg/
dL, respectively, in Group 3 patients.  In Groups 2 and 3, Day 0 CRP levels were higher in 
patients with more severe pneumonia, and signicant differences were found in Day 0 CRP 
levels between patients with mild pneumonia and those with moderate or severe pneumonia. 
The median Day 0 CRP level in patients with moderate or severe pneumonia in Groups 2 
Table 2.  Patient proles
All patients Responders Non-responders P-value
No. patients 242 227 15 （2 deaths）
Mean （median, range） age （years） 59.4 （63, 14-94） 58.6 （62, 14-94） 71.5 （78, 30-89） 0.0226
No. men （%） 133 （55） 127 （56） 　6 （40） 0.2303
Severity of pneumonia†  0.1895＊
　Mild  80 （33%）  75 （33%） 5 （33%）
　Moderate 135 （56%） 129 （57%） 6 （40%）
　Severe  27 （11%）  23 （10%） 4 （27%）
Days from onset until admission  0.0036＊
　0-1 （Group 1）  29 （12%） 27 （12%） 2 （13%）
　2-4 （Group 2） 108 （45%） 96 （42%）  12 （80%）
　≥ 5 （Group 3） 105 （43%） 104 （46%） 　1 （ 7%）
Main co-morbidities†
　Chronic lung disease
　　COPD  35 （14%） 33 2 （13%） 0.8968
　　Asthma  20 （ 8%） 20 0 （ 0%） 0.1019
　　Old TB 　9 （ 4%） 9 0 （ 0%） 0.2785
　　IIPs 　6 （ 2%） 6 0 （ 0%） 0.3778
　　Others 　4 （ 2%） 4 1 （ 7%） 0.2932
　Congestive heart failure  28 （12%） 25 3 （20%） 0.4187
　Cerebrovascular disorder  16 （ 7%） 16 0 （ 0%） 0.1453
　Diabetes  13 （ 5%） 13 0 （ 0%） 0.1908
　Chronic renal failure 　7 （ 3%）  7 0 （ 0%） 0.3403
Pathogens isolated†
　Streptococcus pneumoniae  66 （27%） 64 2 （13%） 0.1805
　Haemophilus inuenzae  25 （10%） 23 2 （13%） 0.7036
　Mycoplasma pneumoniae  23 （10%） 23 0 （ 0%） 0.0784
　Moraxella catarrhalis 　6 （ 2%） 6 0 （ 0%） 0.3778
　Staphylococcus aureus 　2 （ 1%） 2 0 （ 0%） 0.6122
　Legionella spp. 　1 （ 0%） 1 0 （ 0%） 0.7203
　Others 　6 （ 2%） 　5 （ 2%） 1 （ 7%） 0.3640
　None 114 （51%） 104 （46%）  10 （66%） 0.1152
In the present study, responders were dened as those patients with defervescence （temperature＜ 38℃） and 
exhibiting an improvement in symptoms by Day 3. All other patients were classied as non-responders.
＊Comparison among the three groups.
†Data show the number of patients in each group, with percentages given in parentheses.
COPD, chronic obstructive pulmonary disease ; TB, tuberculosis ; IIPs, idiopathic interstitial pneumonia
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and 3 was ≥ 10 mg/dL.
　Figure 1 shows changes in CRP levels in responders with time.  In Group 1, median 
［50% range］ CRP levels on Days 0, 3, and 7 were 6.19 ［3.63-15.27］, 7.03 ［4.58-9.58］, and 
1.44 ［0.77-2.88］mg/dL, respectively, with a transient increase observed on Day 3.  In Group 
2, CRP levels on Days 0, 3, and 7 were 9.85 ［5.11-18.44］, 5.33 ［2.36-9.81］, and 0.81 ［0.30-
1.84］mg/dL, respectively, and in Group 3 the values were 9.99 ［5.01-15.42］, 4.29 ［1.91-6.93］, 
and 0.70 ［0.31-1.97］mg/dL, respectively.  A decrease in CRP levels over time was observed 
Fig. 1.  Changes in C-reactive protein （CRP） levels in responders after the initiation of treatment.
Table 3.  Day 0 C-reactive protein levels, severity of pneumonia, and interval from the onset of pneu-
monia to hospital admission in the 242 patients evaluated in the present study
Group （interval from onset until 
admission）
Severity of CAP （n） Median （range） Day 0
CRP （mg/dL）
P-value
（Wilcoxon test）
Group 1 （0-1 days ; n＝ 29） Mild （2）  4.38 （1.95-6.81）
0.4134
0.7728　
Moderate （24）  6.88 （0.07-39.8）
Severe （3） 0.67（0.12-16.73）
Group 2 （2-4 days ; n＝ 108） Mild （35）  4.88 （1.30-30.95）
0.0002
0.0005　
Moderate （57） 12.40 （0.54-43.12）
Severe （16） 11.21 （4.23-34.89）
Group 3 （≥ 5 days ; n＝ 105） Mild （43）  7.52 （1.42-26.80）
0.0010
0.0100　
Moderate （54） 11.58 （1.27-45.16）
Severe （8） 13.53 （3.44-19.58）
CAP, community-acquired pneumonia ; CRP, C-reactive protein.
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in Groups 2 and 3.
　Comparisons of the percentage changes in CRP levels from Day 0 to Day 3 between 
the responders and non-responders are presented in Table 4.  These comparisons were 
only made for patients in Groups 2 and 3 because there was no correlation between the 
clinical outcome and changes in CRP in Group 1 （Fig. 1）.  Among the responders, the 
median Day 0 CRP level was 9.97 mg/dL, which fell to 4.88 mg/dL on Day 3 （P＜ 0.0001）. 
Compared with the CRP levels on Day 0, CRP levels were lower on Day 3 in 175 of 200 
responders （87.5%）.  In contrast, among the non-responders, the median Day 0 CRP level 
was 4.32 mg/dL and this increased to 11.70 mg/dL on Day 3.  None of the non-responders 
exhibited a decrease in CRP levels on Day 3 to ≤ 50% of values determined in Day 0.
　Univariate logistic regression analysis was performed to investigate the factors that inu-
enced clinical outcome, using age, sex, A-DROP score, Day 0 CRP, Day 3 CRP, and the 
Day 0/Day 3 CRP ratio as variables （Table 5）.  This analysis revealed that Day 3 CRP 
and the Day 0/Day 3 CRP ratio were correlated with clinical outcome.  Multivariate analy-
sis delivered the same result for Day 3 CRP （odds ratio ［OR］＝ 0.884 ; P＝ 0.0429） and 
the Day 0/Day 3 CRP ratio （OR＝ 8.91 ; P＜ 0.0001）, suggesting that an improvement in 
CRP levels by Day 3 or the Day 3 CRP itself could be good indicators of clinical outcome.
Discussion
　In 1930, CRP was reported to react with bacterial capsular polysaccharide and increased 
Table 4.  Changes in C-reactive protein （CRP） levels in relation to clinical outcome and percentage 
changes in CRP from Day 0 to Day 3 in patients in Groups 2 and 3 （n＝ 213）
Clinical outcome n
Median CRP （mg/dL） % Change in CRP on Day 3
Day 0 CRP Day 3 CRP P-value ＜ 50 50-100 ＞ 100
Responders 200 9.97  4.88 ＜ 0.0001 121 55 24
Non-responders  13 4.32 11.70 　0.1465 　0  5  8
In the present study, responders were dened as those patients with defervescence （temperature＜ 38℃） and 
exhibiting an improvement in symptoms by Day 3. All other patients were classied as non-responders.
Table 5.  Univariate analysis of factors inuencing the clinical course 
in patients in Groups 2 and 3 （n＝ 213）
Factor Odds ratio 95% CI P-value
Age 0.965  0.930-0.996 0.0240
Sex （male） 1.40 0.0449-4.48 0.5593
A-DROP score 0.785  0.498-1.29 0.3237
Day 0 CRP 1.05  0.977-1.16 0.1912
Day 3 CRP 0.823  0.735-0.908 ＜ 0.0001
Day 0/Day 3 CRP ratio 9.91   3.64-36.9 ＜ 0.0001
CI, condence interval; CRP, C-reactive protein.
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serum CRP levels were found in patients with pneumococcal infection 13）.  CRP is one of 
the representative acute phase reactants and CRP levels increase markedly in response to 
tissue damage 1）.  Macrophage activation occurs at the site of inammation, followed by the 
production of cytokines, such as interleukin （IL）-6, tumor necrosis factor-α, and IL-1, which 
trigger the release of CRP into the blood from the liver, where it is produced 1, 10）.  Because 
this is a cytokine-mediated response, increases in blood CRP levels can be detected from 
10 h or more after the onset of inammation10）.  The half-life of CRP is several hours 14, 15）, 
thus levels gradually decline with improvement in inammation.  Therefore, changes in CRP 
levels occur slightly later than changes in symptoms.  In the present study, there was no 
correlation between Day 0 CRP levels and the severity of pneumonia in Group 1 patients 
with early disease （Table 3）.  This was probably because the maximum CRP response had 
not occurred at the time of measurement, so the CRP levels did not reect the severity 
of inammation.  However, in Groups 2 and 3, Day 0 CRP levels reected the severity of 
inammation more closely and a good correlation was found between Day 0 CRP and the 
severity of pneumonia, most likely because CRP was measured ≥ 48 h after the onset of 
infection.  Despite improvements in symptoms, Day 3 CRP was higher in Group 1 patients, 
whereas Day 3 CRP decreased with clinical improvement in patients in Groups 2 and 3 
（Fig. 1）.  Therefore, there seems to be a good correlation between Day 0 CRP and the 
severity of pneumonia in patients who have had pneumonia for at least 48 h, and CRP 
levels in these patients decrease markedly with clinical improvement.  As indicated by the 
data in Table 4, Day 3 CRP did not decrease to＜ 50% of the Day 0 value in any of the 
non-responders.  Thus, patients whose Day 3 CRP is＜ 50% of Day 0 CRP are more likely 
to be responders.  Detailed analysis demonstrated that patients with a Day 3 CRP ≤ 15 mg/
dL and＜ 50% of the Day 0 value were likely to be responders （predictive value＝ 1.27 ; 
95% condence interval＝ 0.872-1.97）.
　The results presented in Table 5 also suggest that Day 3 CRP and the percentage change 
in CRP from Day 0 to Day 3 （i.e. the Day 0/Day 3 CRP ratio） are useful for evaluating 
the efcacy of treatment.  Interestingly, there was no correlation between the A-DROP score 
and the response to treatment, which may have been due to the limited number of patients 
investigated and their characteristics （see below）.  Again, the Day 0/Day 3 CRP ratio was 
related to clinical outcome.  This nding is supported by the study of Ruiz-González et al, 
who found that changes in CRP are useful for discrimination between true treatment failure 
and a slow response to treatment 16）.  Accordingly, Day 0 CRP may be an indicator of the 
severity of pneumonia in patients who have had their infection for at least 2 days, whereas 
changes in CRP over time can be useful for evaluating the clinical response.
　Recently, there have been several reports from outside Japan about the usefulness of 
CRP in the management of CAP 4-8）.  Chalmers et al reported that the risk of death or 
mechanical ventilation within 30 days was low in patients with CAP if CRP levels were ≤ 
10 mg/dL at the time of hospital admission, whereas the risk of death within 30 days was 
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increased if the CRP level on Day 3 was ≥ 50% of that on Day 0 4）.  On the basis of our 
ndings, patients with an initial CRP level ≥ 10 mg/dL can be considered as having moder-
ate or severe pneumonia.  Bruns et al 5） studied patients with severe CAP and concluded 
that delayed normalization of CRP was associated with a higher likelihood of inappropriate 
antibiotic treatment.  Menéndez 7） reported that the risk of death within 30 days could be 
predicted more accurately by evaluating CRP in addition to the Pneumonia Severity Index 17） 
and the CURB-65 score.
　Although CRP is widely measured in patients with febrile illness in Japan, there are 
some problems when using it to monitor the progress of infection.  First, CRP levels can 
increase in patients with any inammatory disease and CRP is not specic for infections 1, 10）. 
Conversely, CRP levels will not increase in patients with liver failure or those on anti-IL-6 
therapy, even if they have a severe infection 18, 19）.  Second, CRP is not useful in determin-
ing the causative pathogen.  Third, changes in CRP are often slightly delayed compared 
with changes in symptoms.  Although experienced clinicians understand this characteristic of 
CRP, there is not enough evidence regarding the extent of the delay, and so interpretation 
of CRP data remains dependent on clinical acumen.  The ndings of the present study in 
patients with CAP suggest that measurement of CRP is useful in evaluating the severity 
of the disease and predicting the outcome if levels are determined at least 48 h after the 
onset of pneumonia.  This is the rst report from Japan regarding the usefulness of CRP 
in the management of CAP.  However, the present study was a retrospective study, so the 
differentiation between responders and non-responders may not be sufcient.  In addition, 
because critically ill patients, such as those with pneumonia and respiratory failure, were not 
included in the study （we excluded patients on steroid therapy）, 89% of patients in the 
present study had mild or moderate CAP.  Therefore, the number of non-responders in the 
present study was limited to 15 and this sample may not have been large enough.  Prospec-
tive investigations in a larger patient cohort are needed in the future.
　CRP can be determined in addition to other common laboratory tests in a small venous 
blood sample using a simple, rapid, and inexpensive procedure.  CAP is a disease that doc-
tors frequently encounter in clinical practice 20）, and it is often difcult to decide whether a 
patient requires admission to hospital.  Thus, in addition to assessment of vital signs （includ-
ing blood pressure and oxygen saturation） and chest X-ray ndings, measurement of CRP 
may provide useful information to help doctors decide whether hospital admission is needed 
and to evaluate the response to treatment.
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